Explain this page
Arphra AIPlain-English read on Agree Realty Corporation’s valuation06-03today
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA – ADCT10h
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA – ADCT10h
- Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy2d
- Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy2d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$218.61
+192.54% vs spot
Recommendation
Strong Buy
18 of 19 methods
Method spread
5bull13bear
±5% threshold
Analyst PT consensus: $84.06 (+12.48%)
Candlestick · 1Y
Open in chart workstation →ADC
74.47+4.83%H 82.08L 70.83MA50 76.53MA200 —Avg vol 1.3M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.35% | -1.24% | +0.36% | -6.34% | +5.16% | +3.75% | +1.37% | +13.50% | +6.27% | +65.74% | +283.23% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$75.03
195 sh
Bid
$74.15
1 sh
Ask
$76.00
86 sh
Spread
$1.850
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $200.81M | $62.23M | $0.50 |
| Q4 Dec 2025 | $190.49M | $56.04M | $0.47 |
| Q3 Sep 2025 | $183.22M | $52.12M | $0.45 |
| Q2 Jun 2025 | $175.53M | $49.2M | $0.44 |
| Q1 Mar 2025 | $169.16M | $47M | $0.42 |
| Q4 Dec 2024 | $160.73M | $45.24M | $0.41 |
Sector & industry today
LiveSectors
- Consumer Defensive+0.72%
- Technology+0.67%
- Real Estate+0.47%
- Energy+0.45%
- Industrials-0.32%
- Financial Services-0.45%
- Utilities-0.49%
- Healthcare-0.92%
- Consumer Cyclical-0.94%
- Basic Materials-1.06%
- Communication Services-1.12%
Top industries (issuer's industry highlighted)
- REIT - Retail+0.83%
- Broadcasting-4.30%
- Coal+3.67%
- Hardware, Equipment & Parts-3.62%
- Real Estate - Development-3.31%
- Trucking-3.16%
- Copper-3.02%
- Apparel - Manufacturers-2.63%
- Medical - Equipment & Services-2.31%
- Oil & Gas Energy+2.28%
- Conglomerates-2.28%
- Auto - Dealerships-2.28%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA – ADCTglobenewswire.com·Jun 16, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA – ADCTglobenewswire.com·Jun 16, 2026
- Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategyprnewswire.com·Jun 15, 2026
- Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategyprnewswire.com·Jun 15, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCTprnewswire.com·Jun 11, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCTprnewswire.com·Jun 11, 2026
- Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pgurufocus.com·Jun 11, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCTglobenewswire.com·Jun 09, 2026
Recent analyst activity
DB- Jun 01, 2026PT$84.00Jefferies Assumes Agree Realty (ADC) at BuyJefferies
Peers
No peer list available for ADC.
Total assets
$9.8B
Total debt
$3.35B
Cash & equiv
$16.3M
Operating CF
$504.14M
Free cash flow
$504.14M
Buybacks
-$3.74M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $718.4M | $340.4M | $204.35M | $1.77 | +28.45% |
| FY 2024 | $617.1M | $302.24M | $189.2M | $1.78 | +30.66% |
| FY 2023 | $537.5M | $254.39M | $169.96M | $1.70 | +31.62% |
| FY 2022 | $429.81M | $218.09M | $152.44M | $1.83 | +35.47% |
| FY 2021 | $339.32M | $190.27M | $122.27M | $1.78 | +36.03% |